• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bright Green Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    9/18/24 5:09:35 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BGXX alert in real time by email
    false --12-31 0001886799 0001886799 2024-09-16 2024-09-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported) September 16, 2024

     

    BRIGHT GREEN CORPORATION

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41395   83-4600841

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

     

    1033 George Hanosh Boulevard

    Grants, NM 87020

    (Address of principal executive offices and zip code)

     

    (833) 658-1799

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   BGXX   Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On September 16, 2024, Bright Green Corporation (the “Company”) and Lynn Stockwell (“Lender”) entered into a Secured Amended and Restated Line of Credit Note, which is filed as Exhibit 10.1 to this Current Report on Form 8-K, amending and restating the terms of the original note entered into on November 14, 2022, which was originally amended and restated August 19, 2024 (as amended and restated, the “Note”).

     

    The Note provides, among other things, upon the Lender making a new advance in the principal amount of at least $2,500,000 under the terms of the Note (the “Required Funding”) to be received by the Company no later than two business days following the execution of the Note, all obligations due under the Note shall be secured by (i) a first lien mortgage on the Company’s fee interest in the real property and improvements thereon, including, without limitation, the land, buildings, fixtures, equipment and machinery located at 1033 George Hanosh Blvd, Grants, NM 87020 (the “Property”) and a first priority assignment of leases and rents, (ii) a first priority security interest in all accounts receivable of Company, (iii) an assignment of all contracts, licenses, permits, plans, specifications and other documentation with respect to the Property, and (iv) such other collateral as is customary for a loan of this type, including additional real property if the acquisition of such property occurs while this Note is outstanding.

     

    The Note also provides for a conversion feature pursuant to which Lender may, at Lender’s discretion, convert up to $4 million of the outstanding principal and interest balance of the Note into shares of the Company’s newly designated Series A Preferred Stock, par value $0.0001 (the “Series A Preferred Stock”) at a conversion price of $0.40 per share, provided the Required Funding was received. Further pursuant to the terms of the Note, the Company agreed to file the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Voting Preferred Stock with the Delaware Secretary of State, which is filed as Exhibit 3.1 to this Current Report on Form 8-K (the “Certificate of Designation”), within two business days following receipt of the Required Funding.

     

    Pursuant to the Certificate of Designation, each share of Series A Preferred Stock, subject to the Stockholder Approval (as defined below), shall be convertible at the election of the holder (or automatically if the balance is not repaid by December 31, 2024), into 14 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock” and the shares of Common Stock issuable upon conversion of the Series A Preferred Stock, the “Conversion Shares”). Each share of Series A Preferred Stock is generally entitled to one vote per share, provided that no shares of Series A Preferred Stock are entitled to vote on the proposal related to the Stockholder Approval to occur at a meeting of stockholders. Other than the right of each holder to convert the Series A Preferred Stock into the Conversion Share, subject to the Stockholder Approval, there Series A Preferred Stock has equal distribution and dividend rights as the Common Stock.

     

    Subject to the terms and limitations contained in the Certificate of Designation, the Series A Preferred Stock will not be convertible into Common Stock until the Company’s stockholders approve the issuance of the Conversion Shares upon conversion of the Series A Preferred Stock (the “Stockholder Approval”). The Stockholder Approval is required because, if and when the Conversion Shares would be issued, it represents the issuance of shares of Common Stock by the Company (i) to Lender, a director of the Company, below the “Minimum Value” as defined by The Nasdaq Stock Market, LLC, (ii) representing the potential issuance of more than 19.99% of the outstanding Common Stock of the Company below the “Minimum Price”, and (iii) representing a potential “change of control” of the Company. The Certificate of Designation provides that as soon as practicable, after the Required Funding has been received, the Company will file a preliminary proxy statement for a vote of the Company’s stockholders to approve the issuance of the Conversion Shares, if and when the shares of Series A Preferred Stock are issued upon conversion of the Note.

     

     
     

     

    The Note contains certain representations and warranties, covenants and indemnities customary for similar transactions. The representations, warranties and covenants contained in the Note were made solely for the benefit of the parties to the Note and may be subject to limitations agreed upon by the contracting parties.

     

    The foregoing descriptions of the Certificate of Designation and the Note do not purport to be complete and are qualified in their entirety by the full text of the Certificate of Designation and the Note, which are filed as Exhibit 3.1 and Exhibit 10.1 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.

     

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information contained above in Item 1.01 is hereby incorporated by reference into this Item 2.03.

     

    Item 3.02 Unregistered Sales of Equity Securities.

     

    The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. Upon conversion of the Note, the Series A Preferred Stock, and upon conversion of the Series A Preferred Stock, the Conversion Shares, will be issued without registration under the Securities Act of 1933, as amended, in reliance upon the exemptions therefrom in transactions not involving a public offering, and in reliance on similar exemptions under applicable state laws.

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    The information contained above in Item 1.01 is hereby incorporated by reference into this Item 5.03.

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit Number   Description
    3.1   Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock
    10.1   Secured Amended and Restated Line of Credit Note dated September 16, 2024, between Bright Green Corporation and Lynn Stockwell
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     
     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: September 18, 2024 Bright Green Corporation
         
      By: /s/ Saleem Elmasri
        Saleem Elmasri
        Chief Financial Officer

     

     

     

    Get the next $BGXX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BGXX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGXX
    SEC Filings

    View All

    SEC Form 25-NSE filed by Bright Green Corporation

    25-NSE - Bright Green Corp (0001886799) (Subject)

    3/21/25 11:19:49 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    Bright Green Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bright Green Corp (0001886799) (Filer)

    3/21/25 9:15:14 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    Bright Green Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Financial Statements and Exhibits

    8-K - Bright Green Corp (0001886799) (Filer)

    2/27/25 4:05:24 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    $BGXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Elmasri Saleem sold $4,951 worth of shares (25,942 units at $0.19), decreasing direct ownership by 2% to 1,103,476 units (SEC Form 4)

    4 - Bright Green Corp (0001886799) (Issuer)

    9/11/24 4:05:11 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Elmasri Saleem sold $14,313 worth of shares (71,809 units at $0.20), decreasing direct ownership by 6% to 1,129,418 units (SEC Form 4)

    4 - Bright Green Corp (0001886799) (Issuer)

    9/10/24 4:05:08 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: Chief Executive Officer Singh Gurvinder was granted 5,500,000 shares (SEC Form 4)

    4/A - Bright Green Corp (0001886799) (Issuer)

    9/9/24 4:05:32 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    $BGXX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lynn Stockwell and Bright Green Corporation File $3 Billion Lawsuit Against Rodey Law Firm and Attorneys' Liability Assurance Society (ALAS) for Legal Malpractice and Bad Faith

    Court Found No Wrongdoing by Lynn Stockwell; Judgment Imposed Joint and Several Liability Due to Counsel's Failure Cibola County, New Mexico, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXXQ) and its Chief Executive Officer, Lynn Stockwell, today announced the filing of a landmark lawsuit seeking damages in excess of $3 billion against Rodey Law Firm and Attorneys' Liability Assurance Society (ALAS). The complaint, filed in the Thirteenth Judicial District Court of New Mexico, alleges legal malpractice, breach of contract, and bad faith breach of fiduciary duty. The underlying litigation resulted in findings of no wrongdoing by Lynn Stockwell. Despite this, the court

    1/8/26 9:00:00 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation "BGXXQ" Q and A

    Fort Lauderdale, FL, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PharmAGRI Capital Partners today announced its strategic focus on capturing a $10 billion total addressable market (TAM) in federal procurement of plant-based prescription drugs currently sourced from foreign manufacturers. This segment, while modest in size compared to the broader pharmaceutical industry, represents a critical opportunity to restore control, compliance, and domestic production with a fair transparent pricing model. CEO Statement: "The $10B TAM is not about volume—it's about control. Federal agencies already procure these drugs, often from foreign sources. Our goal is to ensure they contract with a sovereign platfor

    9/16/25 3:14:00 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman

    Tesla Robotics to Power Sovereign "Seed to Syringe" Pharmaceutical Infrastructure Fort Lauderdale, FL, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) has announced its merger with PharmAGRI Capital Partners, a federally aligned pharmaceutical infrastructure platform architected to restore U.S. drug manufacturing sovereignty. The transaction consolidates BGXX's DEA registrations, Board of Pharmacy licensure, audited financials, and Nasdaq history into PharmAGRI under a court-supervised restructuring plan filed in the District of New Mexico. Effective immediately, Lynn Stockwell has been appointed Chief Executive Officer and Chairwoman of PharmAGRI. Ms. Stockwell wi

    9/15/25 8:02:14 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    $BGXX
    Leadership Updates

    Live Leadership Updates

    View All

    (Updated) U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

    Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Jan. 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

    1/14/24 10:00:00 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

    Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

    10/3/23 11:11:00 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    Bright Green Announces First Quarter 2023 Financial Update and Milestone Progress

    Bright Green has achieved several key milestones throughout the Quarter significantly advancing progress against its strategic plan, including a historic DEA Federal Registration and License Approval. Commencement of its fundamental capital raise of $500+ million utilizing the U.S. Citizen & Immigration Services EB-5 program, alongside the recently announced full acquisition of Alterola Biotech, showcases the Company's significant progress against its strategic plan. Company has raised short-term working Capital of $5.26m to commence its operations as it looks to capitalize on its historic DEA Registration in Q2 2023 and beyond. GRANTS, N.M., May 24, 2023 (GLOBE NEWSWIRE) -- Brig

    5/24/23 8:00:00 AM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    $BGXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Bright Green Corporation (Amendment)

    SC 13D/A - Bright Green Corp (0001886799) (Subject)

    9/6/23 5:19:19 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Bright Green Corporation

    SC 13D - Bright Green Corp (0001886799) (Subject)

    6/15/23 4:30:21 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Bright Green Corporation (Amendment)

    SC 13G/A - Bright Green Corp (0001886799) (Subject)

    6/12/23 5:28:12 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care